Monomethyl auristatin D (MMAD), a potent tubulin inhibitor, is a toxin payload and antibody drug conjugate.
Structure of 203849-91-6
* For research and manufacturing use only. We do not sell to patients.
Size | Price | Stock | Quantity |
---|---|---|---|
10 mg | $568 | In stock | |
25 mg | $999 | In stock |
Looking for different specifications? Click to request a custom quote!
Capabilities & Facilities
MMAD (Monomethyl Auristatin D) is a synthetic derivative of dolastatin 10 and a highly potent ADC cytotoxin commonly used as an ADC payload in antibody-drug conjugates. MMAD exerts its cytotoxic effects by binding to tubulin and inhibiting microtubule polymerization, leading to mitotic arrest and apoptosis in rapidly proliferating tumor cells. Its strong antimitotic activity makes it a valuable payload for targeted oncology therapeutics.
In the design of antibody-drug conjugates, MMAD is typically conjugated to monoclonal antibodies via stable or cleavable linker technologies. These linkers ensure that the payload remains inactive in circulation and is released only upon ADC internalization and lysosomal processing within cancer cells. The selective delivery mechanism enhances tumor specificity, reduces systemic toxicity, and allows for potent antitumor activity even at low drug-to-antibody ratios (DARs), which is critical for ADC therapeutic efficacy.
Applications of MMAD include its use in preclinical and clinical ADC candidates targeting both hematologic malignancies and solid tumors, such as lymphoma, multiple myeloma, breast cancer, and lung cancer. Its compatibility with diverse linker chemistries, predictable pharmacokinetics, and high cytotoxic potency make MMAD an ideal choice for ADC research and development. Researchers often employ MMAD to optimize ADC design, evaluate linker stability, and study tumor-selective payload delivery in next-generation antibody-drug conjugates.
What is MMAD?
MMAD (Monomethyl auristatin D) is a synthetic cytotoxic agent used as a payload in ADC research. It targets tubulin to inhibit microtubule formation, providing potent cytotoxic effects for targeted delivery studies in experimental cancer models.
10/4/2018
We would like to know how MMAD functions in ADCs.
MMAD is delivered via antibody conjugation to specific cell targets. After internalization, it disrupts microtubule dynamics, leading to cell cycle arrest and apoptosis, enabling selective cytotoxic activity in research applications.
24/8/2019
We would like to know what types of linkers are suitable for MMAD.
MMAD can be conjugated using cleavable or non-cleavable linkers, including peptide or thioether chemistries. Proper linker selection influences ADC stability, payload release, and cytotoxic efficiency.
8/12/2019
May I ask if BOC Sciences is able to customize MMAD ADCs?
BOC Sciences provides tailored ADC synthesis using MMAD, offering services from linker selection and conjugation optimization to analytical validation, supporting preclinical and laboratory research needs.
24/2/2017
Good afternoon! Could you advise on the recommended storage conditions for MMAD?
MMAD should be stored according to BOC Sciences guidelines, typically at low temperature and protected from light, to preserve chemical integrity and ensure consistent performance in ADC development experiments.
26/8/2018
— Dr. Peter Hall, Senior Scientist (USA)
MMAD provided by BOC Sciences showed high purity and stability, enabling accurate cytotoxicity assays.
8/12/2019
— Dr. Sophia Wright, ADC Chemist (UK)
Excellent support and fast delivery. MMAD met our analytical and regulatory requirements.
26/8/2018
— Dr. Thomas Weber, Medicinal Chemist (Germany)
Reliable batch consistency and professional technical guidance. MMAD enhanced our ADC studies.
24/2/2017
— Dr. Emily Scott, Biochemist (Canada)
Prompt shipment and high-quality compound. MMAD supported our in vitro experiments smoothly.
10/4/2018
— Dr. Daniel Lewis, Principal Investigator (USA)
Comprehensive QC reports and responsive support. MMAD batches were highly consistent.
— Dr. Claire Fontaine, ADC Scientist (France)
Excellent service and dependable supply. MMAD is a trusted cytotoxin for ADC research.
25/8/2019
Contact our experts today for pricing and comprehensive details on our ADC offerings.
From cytotoxin synthesis to linker design, discover our specialized services that complement your ADC projects.
Learn more about payload design, linker strategies, and integrated CDMO support through our curated ADC content.
Find exactly what your project needs from our expanded range of ADCs, offering flexible options to fit your timelines and goals.